EQUILLIUM, INC. (EQ) Free cash flow
- Free cash flow · 12 months (USD): Value $-20.09M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-20.09M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-19.97M − $118.00K ≈ $-20.09M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-19.97M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.11× | Operating cash flow / net income. Period ending 2026-06-30. $-19.97M ÷ $-18.01M ≈ 1.11× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -19.97M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 118.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -20.09M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -18.01M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-20.09M | (m) | $-19.97M | $118.00K | (m) | (m) | (m) | $-18.01M | (m) | (m) | (m) | 1.11× |
| 2026-03-31 | $-18.93M | (m) | $-18.88M | $47.00K | (m) | (m) | (m) | $-19.05M | (m) | (m) | (m) | 0.99× |
| 2025-12-31 | $-22.79M | (m) | $-22.75M | $48.00K | (m) | (m) | (m) | $-22.40M | (m) | (m) | (m) | 1.02× |
| 2025-09-30 | $-22.92M | (m) | $-22.91M | $8.00K | (m) | (m) | (m) | $-24.42M | (m) | (m) | (m) | 0.94× |
| 2025-06-30 | $-22.15M | (m) | $-22.14M | $8.00K | (m) | (m) | (m) | $-20.19M | (m) | (m) | (m) | 1.10× |
| 2025-03-31 | $-18.46M | (m) | $-18.39M | $70.00K | (m) | (m) | (m) | $-13.99M | (m) | (m) | (m) | 1.32× |
| 2024-12-31 | $-19.11M | (m) | $-19.03M | $85.00K | (m) | $41.09M | (m) | $-8.07M | (m) | (m) | -46.50% | 2.36× |
| 2024-09-30 | $-21.51M | (m) | $-21.39M | $116.00K | (m) | $45.91M | (m) | $-4.62M | (m) | (m) | -46.84% | 4.64× |
| 2024-06-30 | (m) | (m) | $-15.64M | (m) | (m) | $42.62M | (m) | $-8.32M | (m) | (m) | (m) | 1.88× |
| 2024-03-31 | (m) | (m) | $-22.59M | (m) | (m) | $37.89M | (m) | $-12.13M | (m) | (m) | (m) | 1.86× |
| 2023-12-31 | $-21.83M | (m) | $-21.78M | $50.00K | (m) | $36.08M | (m) | $-13.34M | (m) | (m) | -60.51% | 1.63× |
| 2023-09-30 | $11.59M | (m) | $11.61M | $17.00K | (m) | (m) | (m) | $-8.22M | (m) | (m) | (m) | -1.41× |
| 2023-06-30 | (m) | (m) | $450.00K | (m) | (m) | (m) | (m) | $-18.16M | (m) | (m) | (m) | -0.02× |
| 2023-03-31 | (m) | (m) | $-4.59M | (m) | (m) | (m) | (m) | $-28.95M | (m) | (m) | (m) | 0.16× |
| 2022-12-31 | $-9.01M | (m) | $-8.73M | $279.00K | (m) | $15.76M | (m) | $-62.43M | (m) | (m) | -57.19% | 0.14× |
| 2022-09-30 | $-46.87M | (m) | $-46.59M | $277.00K | (m) | (m) | (m) | $-75.82M | (m) | (m) | (m) | 0.61× |
| 2022-06-30 | $-40.85M | (m) | $-40.54M | $311.00K | (m) | (m) | (m) | $-72.45M | (m) | (m) | (m) | 0.56× |
| 2022-03-31 | (m) | (m) | $-36.27M | (m) | (m) | (m) | (m) | $-67.48M | (m) | (m) | (m) | 0.54× |
| 2021-12-31 | $-32.14M | (m) | $-32.08M | $57.00K | (m) | (m) | (m) | $-39.05M | (m) | (m) | (m) | 0.82× |
| 2021-09-30 | $-30.29M | (m) | $-30.20M | $87.00K | (m) | (m) | (m) | $-37.35M | (m) | (m) | (m) | 0.81× |
| 2021-06-30 | $-28.32M | (m) | $-28.11M | $210.00K | (m) | (m) | (m) | $-33.66M | (m) | (m) | (m) | 0.84× |
| 2021-03-31 | (m) | (m) | $-26.20M | (m) | (m) | (m) | (m) | $-30.97M | (m) | (m) | (m) | 0.85× |
| 2020-12-31 | $-24.83M | (m) | $-24.62M | $202.00K | (m) | (m) | (m) | $-29.81M | (m) | (m) | (m) | 0.83× |
| 2020-09-30 | $-25.59M | (m) | $-25.40M | $190.00K | (m) | (m) | (m) | $-28.46M | (m) | (m) | (m) | 0.89× |
| 2020-06-30 | $-25.21M | (m) | $-25.18M | $33.00K | (m) | (m) | (m) | $-27.88M | (m) | (m) | (m) | 0.90× |
| 2020-03-31 | $-24.93M | (m) | $-24.86M | $78.00K | (m) | (m) | (m) | $-27.49M | (m) | (m) | (m) | 0.90× |
| 2019-12-31 | $-23.02M | (m) | $-22.95M | $74.00K | (m) | (m) | (m) | $-25.60M | (m) | (m) | (m) | 0.90× |
| 2019-09-30 | $-17.81M | (m) | $-17.74M | $65.86K | (m) | (m) | (m) | $-23.02M | (m) | (m) | (m) | 0.77× |
| 2019-06-30 | $-14.76M | (m) | $-14.69M | $68.86K | (m) | (m) | (m) | $-21.93M | (m) | (m) | (m) | 0.67× |
| 2019-03-31 | $-11.14M | (m) | $-11.10M | $40.86K | (m) | (m) | (m) | $-17.62M | (m) | (m) | (m) | 0.63× |
| 2018-12-31 | $-7.56M | (m) | $-7.53M | $34.86K | (m) | (m) | (m) | $-13.25M | (m) | (m) | (m) | 0.57× |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-4.59M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-3.77M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |